Clene (NASDAQ:CLNN) Given Buy Rating at HC Wainwright

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $31.00 target price on the stock.

Separately, Weiss Ratings raised shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Clene currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Clene Stock Up 4.4%

NASDAQ CLNN traded up $0.14 during trading on Monday, hitting $3.24. The company’s stock had a trading volume of 21,539 shares, compared to its average volume of 220,496. Clene has a 52 week low of $3.02 and a 52 week high of $13.50. The firm has a market cap of $42.04 million, a P/E ratio of -0.93 and a beta of 0.91. The firm has a 50 day moving average price of $4.04 and a 200 day moving average price of $5.33.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Friday, August 14th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.06 million. On average, equities analysts expect that Clene will post -1.70 earnings per share for the current year.

Clene Company Profile

Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.

Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.